MA42988A - Dérivés d'éther spirocycliques de pyrazolo [1,5-a] pyrimidine-3-carboxamide - Google Patents

Dérivés d'éther spirocycliques de pyrazolo [1,5-a] pyrimidine-3-carboxamide

Info

Publication number
MA42988A
MA42988A MA042988A MA42988A MA42988A MA 42988 A MA42988 A MA 42988A MA 042988 A MA042988 A MA 042988A MA 42988 A MA42988 A MA 42988A MA 42988 A MA42988 A MA 42988A
Authority
MA
Morocco
Prior art keywords
pyrazolo
carboxamide
pyrimidine
ether derivatives
spirocyclic
Prior art date
Application number
MA042988A
Other languages
English (en)
Other versions
MA42988B1 (fr
Inventor
Barbara Bertani
Marco Ferrara
Giacomo Fossati
Sara Frattini
Riccardo Giovannini
Scott Hobson
Christoph Hoenke
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA42988A publication Critical patent/MA42988A/fr
Publication of MA42988B1 publication Critical patent/MA42988B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22—Nitrogen atoms not forming part of a nitro radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
MA42988A 2015-10-13 2016-10-12 Dérivés d'éther spirocycliques de pyrazolo [1,5-a] pyrimidine-3-carboxamide MA42988B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15189600.8A EP3156405A1 (fr) 2015-10-13 2015-10-13 Dérivés d'éther spirocycliques de pyrazolo [1,5-a] pyrimidine-3-carboxamide
PCT/EP2016/074380 WO2017064082A1 (fr) 2015-10-13 2016-10-12 Dérivés d'éther cyclique de pyrazolo[1,5-a]pyrimidine-3-carboxyamide

Publications (2)

Publication Number Publication Date
MA42988A true MA42988A (fr) 2021-04-07
MA42988B1 MA42988B1 (fr) 2022-04-29

Family

ID=54293164

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42988A MA42988B1 (fr) 2015-10-13 2016-10-12 Dérivés d'éther spirocycliques de pyrazolo [1,5-a] pyrimidine-3-carboxamide

Country Status (30)

Country Link
US (5) US10023575B2 (fr)
EP (2) EP3156405A1 (fr)
JP (1) JP6626965B2 (fr)
KR (1) KR102611558B1 (fr)
CN (2) CN114181213A (fr)
AU (1) AU2016338602B2 (fr)
BR (1) BR112018004347B1 (fr)
CA (1) CA3001929C (fr)
CL (1) CL2018000856A1 (fr)
CO (1) CO2018003756A2 (fr)
DK (1) DK3362453T3 (fr)
EA (1) EA035350B1 (fr)
ES (1) ES2912223T3 (fr)
HK (1) HK1254651A1 (fr)
HR (1) HRP20220595T1 (fr)
IL (1) IL258070B (fr)
LT (1) LT3362453T (fr)
MA (1) MA42988B1 (fr)
MX (1) MX2018004524A (fr)
MY (1) MY195169A (fr)
NZ (1) NZ740119A (fr)
PE (2) PE20181447A1 (fr)
PH (1) PH12018500796A1 (fr)
PL (1) PL3362453T3 (fr)
PT (1) PT3362453T (fr)
RS (1) RS63218B1 (fr)
SA (1) SA518391334B1 (fr)
SI (1) SI3362453T1 (fr)
UA (1) UA124576C2 (fr)
WO (1) WO2017064082A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3156405A1 (fr) * 2015-10-13 2017-04-19 Boehringer Ingelheim International GmbH Dérivés d'éther spirocycliques de pyrazolo [1,5-a] pyrimidine-3-carboxamide
RU2671964C1 (ru) * 2017-08-30 2018-11-08 Сиа Эволед Пиразоло[1,5-а]пиримидинкарбоксилаты гадолиния и органические светодиоды на их основе
US11498928B2 (en) 2019-01-18 2022-11-15 Ascentage Pharma (Suzhou) Co., Ltd. Macrocyclic spiroethers as Mcl-1 inhibitors
CN110339197A (zh) * 2019-06-24 2019-10-18 中山大学 一种防治血管性痴呆的磷酸二酯酶9a抑制剂的用途

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10108752A1 (de) 2001-02-23 2002-09-05 Bayer Ag Neue Substituierte Imidazotriazinone
CA2494700C (fr) * 2002-08-26 2011-06-28 Takeda Pharmaceutical Company Limited Compose modulateur de recepteur de calcium et utilisation associee
WO2005041957A1 (fr) 2003-10-29 2005-05-12 Pfizer Products Inc. Derives d'oxindole et leur utilisation comme inhibiteurs de la phosphodiesterase de type 2
WO2005061497A1 (fr) 2003-12-16 2005-07-07 Pfizer Products Inc. Pyrido[2,3-d]pyrimidine-2,4-diamines en tant qu'inhibiteurs de la pde 2
EP1548011A1 (fr) 2003-12-23 2005-06-29 Neuro3D Dérivés de 1,4-benzodiazépine-2-one comme inhibiteurs de PDE2 phosphodiesterase, leurs préparation et utilisation thérapeutique
WO2005087751A2 (fr) 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Aspartyle a base d'hydroxyethylamine substitue inhibiteurs de la protease
FR2870539B1 (fr) 2004-05-19 2006-08-04 Greenpharma Sa Sa Nouvelles methodes et medicaments
KR101368093B1 (ko) 2004-09-02 2014-03-14 다케다 게엠베하 트리아졸로프탈라진
AU2006204451C1 (en) 2005-01-05 2012-05-24 Takeda Gmbh Triazolophthalazines as PDE2-inhibitors
EA012505B1 (ru) 2005-01-05 2009-10-30 Никомед Гмбх Триазолофталазины в качестве ингибиторов pde-2
BRPI0502411A (pt) 2005-03-31 2006-11-28 Univ Minas Gerais processo de desenvolvimento de substáncias como inibidores potentes e seletivos de isoformas de fosfodiesterases dos tipos 1 a 5 (pde1,pde2,pde3, pde4, pde5) na base de diocleìna, fluranol ou análogos e suas composições farmacêuticas para o estudo e tratamento de doenças cardiovasculares e produtos associados
US8188097B2 (en) 2005-10-21 2012-05-29 Mitsubishi Tanabe Pharma Corporation Pyrazolo[1,5-A]pyrimidine compounds
JP4847275B2 (ja) * 2005-10-21 2011-12-28 田辺三菱製薬株式会社 ピラゾロ［１，５−ａ］ピリミジン化合物
CN101296699B (zh) * 2005-10-21 2013-01-02 田边三菱制药株式会社 吡唑并[1,5-a]嘧啶化合物
WO2007121319A2 (fr) 2006-04-14 2007-10-25 University Of California Compostions et procédés destinés à déterminer et à prevoir des réponses aux traitements de la dépression et de l'anxiété
TW201345908A (zh) 2006-07-05 2013-11-16 Mitsubishi Tanabe Pharma Corp 吡唑并〔１，５-ａ〕嘧啶化合物
AR061793A1 (es) 2006-07-05 2008-09-24 Mitsubishi Tanabe Pharma Corp Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
DE102006048693A1 (de) 2006-10-14 2008-04-17 Bayer Healthcare Ag Inhibition der PDE2A
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
SG194397A1 (en) 2008-10-31 2013-11-29 Genentech Inc Pyrazolopyrimidine jak inhibitor compounds and methods
CA2750935A1 (fr) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryles et applications associees
WO2012021615A1 (fr) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Hétéroaryles et utilisations
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
WO2013034761A1 (fr) 2011-09-09 2013-03-14 H. Lundbeck A/S Composés de pyridine et leurs utilisations
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
WO2014025651A1 (fr) * 2012-08-06 2014-02-13 Amgen Inc. Dérivés de chromane en tant qu'inhibiteurs de trpm8
JPWO2015012328A1 (ja) 2013-07-24 2017-03-02 武田薬品工業株式会社 複素環化合物
EP3061754A4 (fr) 2013-10-23 2017-03-22 Takeda Pharmaceutical Company Limited Composé hétérocyclique
US9815796B2 (en) 2013-12-23 2017-11-14 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as PDE2 inhibitors
EP3156405A1 (fr) * 2015-10-13 2017-04-19 Boehringer Ingelheim International GmbH Dérivés d'éther spirocycliques de pyrazolo [1,5-a] pyrimidine-3-carboxamide
JP2017095366A (ja) * 2015-11-18 2017-06-01 持田製薬株式会社 新規ビアリールアミド誘導体

Also Published As

Publication number Publication date
SI3362453T1 (sl) 2022-06-30
CO2018003756A2 (es) 2018-07-10
HRP20220595T1 (hr) 2022-06-10
MX2018004524A (es) 2018-06-27
US10479794B2 (en) 2019-11-19
KR102611558B1 (ko) 2023-12-11
US20180134720A1 (en) 2018-05-17
EP3156405A1 (fr) 2017-04-19
EP3362453A1 (fr) 2018-08-22
RS63218B1 (sr) 2022-06-30
US20230286993A1 (en) 2023-09-14
US20210032259A1 (en) 2021-02-04
PT3362453T (pt) 2022-05-04
UA124576C2 (uk) 2021-10-13
IL258070B (en) 2020-06-30
US20200039991A1 (en) 2020-02-06
AU2016338602A1 (en) 2018-03-15
JP6626965B2 (ja) 2019-12-25
CN114181213A (zh) 2022-03-15
HK1254651A1 (zh) 2019-07-26
MY195169A (en) 2023-01-11
US20170101411A1 (en) 2017-04-13
EA035350B1 (ru) 2020-05-29
CL2018000856A1 (es) 2018-07-27
IL258070A (en) 2018-05-31
US10875867B2 (en) 2020-12-29
US10023575B2 (en) 2018-07-17
BR112018004347B1 (pt) 2023-12-05
PE20181447A1 (es) 2018-09-12
PL3362453T3 (pl) 2022-07-25
WO2017064082A1 (fr) 2017-04-20
BR112018004347A2 (pt) 2018-10-09
CA3001929C (fr) 2023-11-28
DK3362453T3 (da) 2022-06-07
ES2912223T3 (es) 2022-05-25
AU2016338602B2 (en) 2020-07-16
JP2018534279A (ja) 2018-11-22
LT3362453T (lt) 2022-05-25
SA518391334B1 (ar) 2021-03-29
CN108137602A (zh) 2018-06-08
NZ740119A (en) 2022-02-25
CA3001929A1 (fr) 2017-04-20
EA201890922A1 (ru) 2018-11-30
PH12018500796A1 (en) 2018-10-29
EP3362453B1 (fr) 2022-03-30
MA42988B1 (fr) 2022-04-29
PE20190778A1 (es) 2019-06-06
US11691977B2 (en) 2023-07-04
CN108137602B (zh) 2021-09-28
KR20180063316A (ko) 2018-06-11

Similar Documents

Publication Publication Date Title
MA52987A (fr) Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak
MA47500A (fr) Dérivés de pyrrolo [1,2-b]pyridazine
HK1256751A1 (zh) [1，2，4]三唑並[1，5-a]嘧啶-7-基化合物
EP3107914B8 (fr) Pyrazolo[1,5-a]pyrimidine-5,7-diamines en tant qu'inhibiteurs de cdk et leur utilisation thérapeutique
DK3134413T3 (da) Substituerede [1,2,4]triazolo[1,5-a]pyrimidin-7-yl-forbindelser som pde2-inhibitorer
DK3418281T3 (da) Pyrazolo[1,5-a]pyrimidiner, der er anvendelige som inhibitorer af atr-kinase til behandling af cancersygdomme
MA43021A (fr) Nouveaux dérivés pyrrolo [2,3-d]pyrimidine utilisés en tant qu'inhibiteurs doubles de dyrk1/clk1
ZA201701814B (en) Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2
MA42988A (fr) Dérivés d'éther spirocycliques de pyrazolo [1,5-a] pyrimidine-3-carboxamide
ZA201605666B (en) Pyrazolo[1,5-a]pyrimidines as antiviral compounds
MA46690A (fr) Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2
TH1601001194A (th) อนุพันธ์ไตรอะโซโล[4,5-d]ไพริมิดีน ใหม่
TH1601003657A (th) อนุพันธ์ [1,2,4] ไตรอะโซโล [1,5-a]ไพริมิดีน ดังสารยับยั้งโปรเตียโซมของ โปรโตซัวสำหรับการรักษาของโรคที่เกิดจากปรสิต เช่น โรคลิชมาเนียซิส